Latest Conference Articles

KALAHARI study: Phase 2 early results indicate alternative treatment pathway for patients with DME is effective, durable

KALAHARI study: Phase 2 early results indicate alternative treatment pathway for patients with DME is effective, durable

July 16th 2022

ASRS

Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study),” which he presented in New York City, New York.

Elevated albumin to creatinine ratio associated with central subfield thickness fluctuations in patients with DME

Elevated albumin to creatinine ratio associated with central subfield thickness fluctuations in patients with DME

July 16th 2022

ASRS

At ASRS in New York, Matthew Starr, MD, presented, “Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases.”

RGX-314 demonstrates DRSS improvements in patients with DME, NPDR

RGX-314 demonstrates DRSS improvements in patients with DME, NPDR

July 15th 2022

ASRS

At ASRS in New York City, Charles Wykoff, MD, presented a talk entitled, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” The trial demonstrated large improvements for patients with diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), with notable improvements according to the Diabetic Retinopathy Severity Scale (DRSS).

New tool emerges for predicting the risk of vision loss from diabetic retinopathy

New tool emerges for predicting the risk of vision loss from diabetic retinopathy

July 15th 2022

ASRS

The future risk of the development of new-onset vision-threatening diabetic retinopathy, diabetic macular edema, and proliferative diabetic retinopathy can be predicted using the patient’s retinopathy status and hemoglobin A1c value.

Metformin may have a protective effect against AMD

Metformin may have a protective effect against AMD

July 15th 2022

ASRS

Metformin, a frequently prescribed drug to treat diabetes, could be a novel therapy for AMD.

DAVIO trial: 12-month results show favorable safety profile, reduced treatment burden in patients with nAMD

DAVIO trial: 12-month results show favorable safety profile, reduced treatment burden in patients with nAMD

July 15th 2022

ASRS

At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.

TOWER study: A new index to measure retinal fluid fluctuations in the retina in wet AMD

TOWER study: A new index to measure retinal fluid fluctuations in the retina in wet AMD

July 15th 2022

ASRS

Investigators from Thailand took a close look at retinal fluid fluctuations in Thai patients with wet age-related macular degeneration (AMD) and devised a better way to measure the fluctuations in the central subfield thickness (CST).

PEACHTREE post hoc analysis: Significant reduction of macular edema, low rate of rescue in patients with chronic uveitis

PEACHTREE post hoc analysis: Significant reduction of macular edema, low rate of rescue in patients with chronic uveitis

July 14th 2022

ASRS

Christopher Henry, MD, presented a talk entitled, “Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis,” at ASRS 2022 in New York City, New York.

Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuity

Pediatric retinal detachment surgery in the US: Primary scleral buckling achieved best visual acuity

July 14th 2022

ASRS

Rhegmatogenous detachments increased with age; myopia, trauma, and history of retinopathy were common underlying risk factors for development of rhegmatogenous retinal detachments.

DME: Faricimab remains durable, effective in 2-year results of YOSEMITE and RHINE trials

DME: Faricimab remains durable, effective in 2-year results of YOSEMITE and RHINE trials

July 14th 2022

ASRS

At ASRS in New York City, New York, David Eichenbaum, MD, presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”